MeSH D000592 - inborn errors amino acid metabolism
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D008661:Inborn errors metabolism
D000592:
Inborn errors amino acid metabolism
D000474:Alkaptonuria
0 Companies
0 Drugs
Success rate
D008375:Maple syrup urine disease
0 Companies
0 Drugs
Success rate
D009100:Multiple carboxylase deficiency
0 Companies
0 Drugs
Success rate
D010661:Phenylketonurias
D020138:Hyperhomocysteinemia
0 Companies
0 Drugs
Success rate
D020158:Nonketotic hyperglycinemia
0 Companies
0 Drugs
Success rate
D020167:Hyperlysinemias
0 Companies
0 Drugs
Success rate
D020176:Tyrosinemias
D054069:Multiple acyl coenzyme a dehydrogenase deficiency
0 Companies
0 Drugs
Success rate
D056732:Prolidase deficiency
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Eurocept International | Carglumic acid | Ucedane | 2017-06-23 | |||
| Recordati | Carglumic acid | Carbaglu | 2003-01-24 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/3
Phase 3
100%1/1
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use